Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
The Cyclin-dependent kinase 4 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development Cyclin-dependent kinase 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cyclin-dependent kinase 4 and features dormant and discontinued projects.
Key Therapy Areas in the Cyclin-dependent kinase 4 Pipeline Drugs Market
The key therapy areas in the Cyclin-dependent kinase 4 pipeline drugs market are Oncology, Infectious disease, Toxicology, Undisclosed, and Genetic Disorders.
Cyclin-dependent kinase 4 Drugs Market, by Therapy Areas
For more target insights, download a free report sample
Key MoA in the Cyclin-dependent kinase 4 Pipeline Drugs Market
The key mechanism of action in the Cyclin-dependent kinase 4 pipeline drugs market is Cyclin Dependent Kinase 4 Inhibitor.
Cyclin-dependent kinase 4 Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Cyclin-dependent kinase 4 pipeline drugs market are Intravenous, and Oral.
Cyclin-dependent kinase 4 Pipeline Drugs Market, by RoA
For more company insights, download a free sample report
Key Molecule Types in the Cyclin-dependent kinase 4 Pipeline Drugs Market
The key molecule types in Cyclin-dependent kinase 4 pipeline drugs market are Monoclonal Antibody, and Small Molecule.
Cyclin-dependent kinase 4 Pipeline Drugs Market, by Major Molecules
For more company insights, download a free sample report
Major Companies in the Cyclin-dependent kinase 4 Pipeline Drugs Market
The major companies in the Cyclin-dependent kinase 4 pipeline drugs market are G1 Therapeutics Inc, Travecta Therapeutics Inc, ViroStatics SRL, Sanofi, Tetranov International Inc, Shanghai Pharmaceutical Group Co Ltd, Sihuan Pharmaceutical Holdings Group Ltd, and Sino Biopharmaceutical Ltd among others.
Cyclin-dependent kinase 4 Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Cyclin-dependent kinase 4 Pipeline Drugs Market Overview
| Key Therapy Areas | Oncology, Infectious disease, Toxicology, Undisclosed, and Genetic Disorders |
| Key Mechanisms of action | Cyclin Dependent Kinase 4 Inhibitor |
| Key Routes of Administration | Intravenous, and Oral |
| Key molecule types | Monoclonal Antibody, and Small Molecule |
| Major companies | G1 Therapeutics Inc, Travecta Therapeutics Inc, ViroStatics SRL, Sanofi, Tetranov International Inc, Shanghai Pharmaceutical Group Co Ltd, Sihuan Pharmaceutical Holdings Group Ltd, and Sino Biopharmaceutical Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cyclin-dependent kinase 4
- The pipeline guide reviews pipeline therapeutics for Cyclin-dependent kinase 4 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cyclin-dependent kinase 4 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cyclin-dependent kinase 4 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Cyclin-dependent kinase 4
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cyclin-dependent kinase 4
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cyclin-dependent kinase 4 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
Cothera Bioscience Pty Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ESSA Pharma Inc
Fochon Pharmaceutical Ltd
G1 Therapeutics Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HEC Pharma Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Nuvation Bio Inc
Onconova Therapeutics Inc
OnQuality Pharmaceuticals LLC
Pfizer Inc
Prelude Therapeutics Inc
Qilu Regor Therapeutics Inc
Rhizen Pharmaceuticals SA
Rizen (Suzhou) Biosciences Co Ltd
Sanofi
SATT Conectus Alsace SAS
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Xunhe Pharmaceutical Technology Co Ltd
Shengke Pharmaceuticals (Jiangsu) Ltd
SignalRx Pharmaceuticals Inc
Sihuan Pharmaceutical Holdings Group Ltd
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Tetranov International Inc
Tiziana Life Sciences Plc
Travecta Therapeutics Inc
ViroStatics SRL
Table of Contents
Frequently asked questions
-
What are the key therapy areas in the Cyclin-dependent kinase 4 pipeline drugs market?
The key therapy areas in the Cyclin-dependent kinase 4 pipeline drugs market are Oncology, Infectious disease, Toxicology, Undisclosed, and Genetic Disorders.
-
What are the key mechanisms of action in the Cyclin-dependent kinase 4 pipeline drugs market?
The key mechanism of action in the Cyclin-dependent kinase 4 pipeline drugs market is Cyclin Dependent Kinase 4 Inhibitor.
-
What are the key routes of administration in the Cyclin-dependent kinase 4 pipeline drugs market?
The key routes of administration in the Cyclin-dependent kinase 4 pipeline drugs market are Intravenous, and Oral.
-
What are the key molecule types in the Cyclin-dependent kinase 4 pipeline drugs market?
The key molecule types in the Cyclin-dependent kinase 4 pipeline drugs market are Monoclonal Antibody, and Small Molecule.
-
What are the major companies in the Cyclin-dependent kinase 4 pipeline drugs market?
The major companies in the Cyclin-dependent kinase 4 pipeline drugs market are G1 Therapeutics Inc, Travecta Therapeutics Inc, ViroStatics SRL, Sanofi, Tetranov International Inc, Shanghai Pharmaceutical Group Co Ltd, Sihuan Pharmaceutical Holdings Group Ltd, and Sino Biopharmaceutical Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports